<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853602</url>
  </required_header>
  <id_info>
    <org_study_id>IFx-Hu2.0 Expanded Access</org_study_id>
    <nct_id>NCT04853602</nct_id>
  </id_info>
  <brief_title>IFx-Hu2.0 Expanded Access Program</brief_title>
  <official_title>IFx-Hu2.0 Expanded Access Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morphogenesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Morphogenesis, Inc.</source>
  <brief_summary>
    <textblock>
      Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients&#xD;
      (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma,&#xD;
      advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC)&#xD;
      who have failed all available treatment options.&#xD;
&#xD;
      To request access, use Responsible Party contact information provided in this record.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Cutaneous Melanoma, Stage III</condition>
  <condition>Cutaneous Melanoma, Stage IV</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFx-Hu2.0</intervention_name>
    <description>The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.&#xD;
Therapeutic Classification:&#xD;
Immunomodulatory Agent&#xD;
Route of Administration:&#xD;
Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)&#xD;
Mechanism of Action:&#xD;
Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.&#xD;
Physiological Effect:&#xD;
Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance.</description>
    <other_name>pAc/emm55</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To request more information use Responsible Party contact information provided in this&#xD;
             record&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To request more information use Responsible Party contact information provided in this&#xD;
             record&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>James A Bianco, MD</last_name>
    <phone>813-875-6600</phone>
    <phone_ext>104</phone_ext>
    <email>jbianco@morphogenesis-inc.com</email>
  </overall_contact>
  <link>
    <url>https://morphogenesis-inc.com/clinical-trials</url>
    <description>Clinical Trials</description>
  </link>
  <link>
    <url>https://morphogenesis-inc.com/expanded-access-policy</url>
    <description>Expanded Access Policy</description>
  </link>
  <reference>
    <citation>Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother. 2020 Dec;69(12):2465-2476. doi: 10.1007/s00262-020-02634-4. Epub 2020 Jun 18.</citation>
    <PMID>32556443</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CM</keyword>
  <keyword>MCC</keyword>
  <keyword>cSCC</keyword>
  <keyword>pDNA</keyword>
  <keyword>plasmid DNA</keyword>
  <keyword>pAc/emm55</keyword>
  <keyword>IFx-Hu.20</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Immunology</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

